Company news

Senti Biosciences Holdings, Inc. news in 2025

Senti Biosciences Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Senti Biosciences Announces New Employment Inducement Grants

December 18, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

December 9, 2025

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

December 9, 2025

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8: 00 AM ET

December 4, 2025

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

November 13, 2025

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

November 3, 2025

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

October 16, 2025

Senti Bio to Present at BioJapan

October 6, 2025

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

September 18, 2025

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

August 12, 2025

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

August 7, 2025

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

August 5, 2025

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 22, 2025

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

July 21, 2025

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

July 18, 2025

Senti Bio Participates in Nasdaq Amplify Spotlight Series

June 30, 2025

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

June 24, 2025

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

June 18, 2025

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

June 6, 2025

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 22, 2025

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 8, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

May 6, 2025

Senti Bio Releases Virtual Investor “What This Means” Segment

May 1, 2025

Senti Bio to Present at the Citizens JMP Life Sciences Conference

April 30, 2025

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

April 28, 2025

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8: 30 AM ET

April 24, 2025

Senti Bio Participates in a Virtual Investor KOL Connect Segment

April 21, 2025

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

April 16, 2025

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

April 10, 2025

Senti Bio Joins Webull Corporate Connect Service Platform

April 7, 2025

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 3, 2025

Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights

March 20, 2025

Senti Bio Appoints Feng Hsiung to Board of Directors

March 13, 2025

Senti Bio Strengthens Leadership Team with Strategic Hires

February 25, 2025

Senti Bio Announces Additional $11.5 Million of Financing

January 5, 2025

Decks in 2025